Prior authorization is the tax you pay for practicing medicine in the American system. If you run a compounding-focused or concierge practice, you already know the arithmetic: a medical assistant spends 30 to 90 minutes on a single PA, most of it repeating information that already lives in your chart. Multiply that by the volume of GLP-1 requests, hormone therapies, specialty medications, and imaging orders flowing through a typical week, and you have a full FTE dedicated to fax machines and hold music.

AI can meaningfully change that math. Not by replacing your staff, but by taking the repetitive extraction and drafting work off their plates so they can focus on the parts that actually require judgment. Here is how we think about it as operators, what actually works, and what to watch for before you buy anything.

Where the time actually goes

When we audit PA workflows at practices onboarding to Qintara, the same pattern shows up. Staff time on a given authorization breaks down roughly like this:

  • Identifying which payer requires PA for which drug or service, and finding the current form
  • Pulling clinical documentation from the chart (labs, vitals, prior therapies tried, ICD-10 codes, notes supporting medical necessity)
  • Transcribing that information into the payer's portal or PDF
  • Waiting on hold, submitting, resubmitting, and following up
  • Handling denials and drafting appeals

The first three steps are almost entirely mechanical. They require accuracy and attention, not clinical reasoning. That is exactly where AI assistance earns its keep. The last two are where a human still needs to be in the loop, but even there, a well-designed system can draft the appeal letter and surface the specific policy language you need to cite.

What "AI-assisted" should actually mean

There is a lot of vendor noise in this space. Strip away the marketing and a useful PA assistant does four concrete things.

1. Detects when a PA is likely required, before the patient leaves

The worst version of this workflow is finding out a PA is needed three days after the visit, when the pharmacy calls. A decent AI layer checks payer, plan, medication or CPT code, and formulary status at the point of ordering, then flags the order in real time. Your prescriber knows before they sign. Your MA starts the PA that day, not next week.

2. Extracts the right clinical evidence from the chart

This is the piece that saves the most time. Given a drug and a payer's criteria (say, a step-therapy requirement or a documented BMI threshold), the system pulls the relevant labs, prior medication trials, diagnoses, and note excerpts and assembles them into a draft. Your staff reviews and edits rather than hunts and pecks.

3. Drafts the submission and the letter of medical necessity

A good draft cites specific chart evidence, matches the payer's language, and formats correctly for the portal or form. The clinician's role becomes review and signature, which is what it should have been all along.

4. Tracks status and drafts appeals on denial

Denials often turn on a missing element that was in the chart but not in the submission, or on a policy the reviewer misapplied. An AI agent can read the denial reason, compare it against the original submission and chart, and produce a targeted appeal draft in minutes.

What this looks like on the floor

A concierge internist we work with was averaging 11 PAs per week across GLP-1s, testosterone therapy, and a handful of specialty referrals. Their MA was spending about 9 hours a week on the workflow, and the practice was eating denials they did not have time to appeal.

After moving PA drafting into their EMR workflow with an AI agent handling extraction and letter generation, the time-per-PA dropped from around 45 minutes to roughly 8 minutes of human review. More importantly, the appeal rate on denials went up because appeals were no longer a "if we get to it" task. Recovered revenue from appeals that would have been abandoned covered the tooling several times over.

The pattern is consistent across practices: the labor savings are real, but the recovered revenue from actually pursuing appeals is often the larger number.

What to watch for before you buy

A few things separate tools that work from tools that create new problems.

It has to live inside your clinical workflow. A PA tool that requires your staff to log into a separate portal, copy patient data over, and toggle back to the EMR is a tax, not a solution. The extraction only works if the AI has native access to the chart. This is a big part of why we built PA workflows directly into the Qintara EMR rather than as a bolt-on.

Humans stay in the loop on anything clinical. The AI drafts. A clinician or trained staff member reviews and signs. If a vendor tells you their system submits without human review, that is a compliance and liability posture I would not want to defend. Talk to your own counsel about your state's rules and your malpractice carrier's expectations.

Audit trails matter. You need to be able to show, months later, who reviewed the AI draft, what was changed, and what was submitted. This is basic hygiene for both payer disputes and any regulatory conversation.

Payer coverage is uneven. Some payers have clean APIs. Many still require portal submission or fax. A useful tool handles the messy long tail, not just the easy 20 percent.

Watch for hallucinated evidence. The failure mode you cannot tolerate is an AI that fabricates a lab value or a prior therapy trial to fit the criteria. Ask vendors specifically how they constrain the model to cite only chart-sourced facts, and how they surface those citations to the reviewer.

Practical steps if you want to start

You do not need to overhaul everything at once. A reasonable sequence:

  • Pick the two or three medications or procedures that drive most of your PA volume. For many compounding and concierge practices, that is GLP-1s, HRT, and a handful of specialty items.
  • Document your current process end to end, including who touches what and how long it takes. You need a baseline to measure against.
  • Pilot AI-assisted drafting on that narrow slice for 30 to 60 days. Track time per PA, first-pass approval rate, denial rate, and appeal rate.
  • Expand from there. The workflow patterns are similar across drug classes; once your staff trusts the drafts, adoption accelerates.

If you want to see what an EMR looks like when PA, refills, intake, and communication are all built on the same underlying agent infrastructure rather than stitched together, talk to our team. We built this for practices that were tired of paying the administrative tax.

Frequently Asked Questions

Does using AI for prior authorizations create compliance risk?

The risk profile is manageable when the AI drafts and a licensed human reviews and submits. Keep clear audit trails, do not let the system submit clinical attestations without human sign-off, and confirm your specific setup with your own counsel and your malpractice carrier. Rules vary by state and payer.

How accurate does the AI extraction need to be?

Extraction accuracy on structured fields (labs, ICD-10 codes, medication history) should be very high, because those live in discrete chart fields. Narrative extraction from notes is harder. The right posture is to treat every AI-produced draft as a draft, with source citations back into the chart so the reviewer can verify in seconds rather than minutes.

What kind of ROI is realistic?

Two places to look. First, staff hours reclaimed, which is straightforward to calculate against your current PA volume. Second, revenue that was previously walking out the door because your team did not have bandwidth to appeal denials. In our experience the appeal recovery is often the larger number, but it depends heavily on your payer mix and drug categories.

Will payers push back on AI-generated submissions?

Payers care about the content and accuracy of the submission, not the drafting method. A well-formed submission with correct clinical evidence and appropriate signatures is a well-formed submission. Payers themselves use automation on the review side, often more aggressively than practices do.

What about drugs with no established payer criteria, like many compounded medications?

PA is less relevant here because these are often cash-pay. The bigger operational lift for compounding practices tends to be intake, eligibility, refill workflows, and pharmacy coordination. Those are the same problems, just wearing a different jersey, and the same agent infrastructure that handles PA can handle them.